Arch Financial Statements From 2010 to 2025
| ACHFF Stock | USD 0.88 0.03 3.30% |
Check Arch Biopartners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arch Biopartners' main balance sheet or income statement drivers, such as , as well as many indicators such as . Arch financial statements analysis is a perfect complement when working with Arch Biopartners Valuation or Volatility modules.
Arch |
Arch Biopartners OTC Stock Shares Outstanding Analysis
Arch Biopartners' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Arch Biopartners Shares Outstanding | 62.4 M |
Most of Arch Biopartners' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arch Biopartners is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Arch Biopartners has 62.4 M of shares currently outstending. This is 65.44% lower than that of the Healthcare sector and 41.6% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 89.09% higher than that of the company.
Arch Biopartners Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arch Biopartners's current stock value. Our valuation model uses many indicators to compare Arch Biopartners value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arch Biopartners competition to find correlations between indicators driving Arch Biopartners's intrinsic value. More Info.Arch Biopartners is rated below average in return on asset category among its peers. It is rated fourth in profit margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arch Biopartners' earnings, one of the primary drivers of an investment's value.About Arch Biopartners Financial Statements
Arch Biopartners stakeholders use historical fundamental indicators, such as Arch Biopartners' revenue or net income, to determine how well the company is positioned to perform in the future. Although Arch Biopartners investors may analyze each financial statement separately, they are all interrelated. For example, changes in Arch Biopartners' assets and liabilities are reflected in the revenues and expenses on Arch Biopartners' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Arch Biopartners. Please read more on our technical analysis and fundamental analysis pages.
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Arch OTC Stock
Arch Biopartners financial ratios help investors to determine whether Arch OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arch with respect to the benefits of owning Arch Biopartners security.